Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal
Sarepta’s lead gene therapy $SRPT may be on clinical hold, but the brash Duchenne muscular dystrophy company is continuing its deep dive into the field …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
